 |
 |
|
 |
Johnson and Johnson (JNJ) |
|
 |
|
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Earnings Schedule |
 |
|
Johnson and Johnson (JNJ) | Healthcare |
|
Today's Week |
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
Yahoo |
|
|
|
| |
|
|
|
|
| |
|
| FISCAL YEAR |
What is US Fiscal Year?
The US fiscal 2025 first quarter is from October 1, 2024, to December 31, 2024, which is the final quarter of the 2024 calendar year, while the US fiscal 2025 quarters run from October 1, 2024, through September 30, 2025.
US Fiscal Year: The U.S. government's fiscal year runs from October 1 to September 30.
Fiscal 2025 (FY25): This period begins on October 1, 2024, and ends on September 30, 2025.
First Quarter (Q1): The first quarter of FY25 is October 1, 2024, to December 31, 2024.
Other Quarters of FY25:
Q2: January 1, 2025–March 31, 2025
Q3: April 1, 2025–June 30, 2025
Q4: July 1, 2025–September 30, 2025
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Earnings News |
|
|
Johnson and Johnson (JNJ) | Healthcare |
|
Today's Week |
|
|
|
|
|
|
|
|
|
|
|
|
|
Johnson and Johnson | Technology Sector
| DATE/WEEK |
HIGHLIGHTS |
FOR |
EPS |
|
JNJ |
No 4 |
... |
|
Q2-2027 |
|
| |
|
|
|
JNJ |
No 3 |
... |
|
Q1-2027 |
|
| |
|
|
|
JNJ |
No 2 |
... |
|
Q4-2026 |
|
| |
|
|
|
Johnson & Johnson forecasts 2026 profit above Wall Street estimates. Johnson & Johnson
on Wednesday forecast 2026 sales and profit ahead of Wall Street estimates, even when including a hit of “hundreds of millions of dollars” from the drug pricing deal it signed with the Trump administration earlier this month.The company forecast 2026 operational sales of $99.5 billion to $100.5 billion, exceeding analysts’ estimates of $98.9 billion, according to LSEG data. J&J sees full-year 2026 profit coming in at $11.43 to $11.63 per share. Analysts have forecast earnings of $11.45 per share.On an adjusted basis, the healthcare conglomerate earned $6 billion, or $2.46 per share, for the quarter. Analysts were expecting a profit of $2.44 per share. Quarterly revenue of $24.56 billion also topped Wall Street expectations of $24.16 billion. |
No 1 |
... |
|
Q3-2026 |
|
| |
|
|
 |
|
Johnson & Johnson (JNJ) Beats Q3 Earnings and Revenue Estimates. Johnson & Johnson (JNJ) came out with quarterly earnings of $2.8 per share, beating the Zacks Consensus Estimate of $2.77 per share. This compares to earnings of $2.42 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +1.08%. A quarter ago, it was expected that this world's biggest maker of health care products would post earnings of $2.66 per share when it actually produced earnings of $2.77, delivering a surprise of +4.14%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. |
No 4 |
... |
|
Q3-2025 |
|
| |
|
|
|
Johnson & Johnson (JNJ) Q2 2025 Earnings Call Highlights: Strong Sales Growth Amid Challenges. Diluted Earnings Per Share (EPS): $2.29, up from $1.93 a year ago.Adjusted Diluted EPS: $2.77, a 1.8% decrease from the previous year. Johnson & Johnson (NYSE:JNJ) reported a strong operational sales growth of 4.6% across its business in the second quarter of 2025.The company achieved over $15 billion in quarterly sales for the first time in its Innovative Medicine segment, despite the loss of exclusivity for STELARA. |
No 3 |
... |
|
Q2-2025 |
|
| |
|
|
|
Johnson & Johnson (JNJ) on Tuesday reported better-than-expected first-quarter results and lifted its sales forecast for the full year. The pharmaceutical and medical technology firm posted adjusted earnings per share (EPS) of $2.77 on revenue of $21.89 billion. Analysts had expected $2.56 and $21.56 billion, respectively, according to estimates compiled by Visible Alpha.The company lifted its projected operating sales range to $91.0 billion to $91.8 billion, up from $89.2 billion to $90.0 billion previously. It also held its adjusted EPS forecast steady at $10.50 to $10.70, "including tariff costs, dilution from the Intra-Cellular Therapies acquisition, and updated foreign exchange."Johnson & Johnson Tops Q1 Estimates, Lifts Full-Year Sales Outlook |
No 2 |
$10.50 |
|
Q1-2025 |
|
| |
|
|
|
J&J beats quarterly sales and profit estimates on cancer drug sales. Johnson & Johnson fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments. The New Jersey-based drugmaker also said it expects 2025 sales of between $90.9 billion and $91.7 billion and earnings between $10.75 and $10.95 per share on an adjusted basis. Analysts were expecting sales of $90.98 billion and a profit of $10.56 per share for 2025, according to data compiled by LSEG. |
No 1 |
... |
|
Q4-2024 |
|
| |
|
|
|
|
Johnson & Johnson (JNJ) Reports Q3 Earnings: What Key Metrics Have to Say. For the quarter ended September 2024, Johnson & Johnson (JNJ) reported revenue of $22.47 billion, up 5.3% over the same period last year. EPS came in at $2.42, compared to $2.66 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $22.19 billion, representing a surprise of +1.27%. The company delivered an EPS surprise of +9.01%, with the consensus EPS estimate being $2.22.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. |
No 4 |
... |
|
Q3-2024 |
|
| |
|
|
|
J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs. Johnson & Johnson’s JNJ second-quarter 2024 earnings came in at $2.82 per share, which beat the Zacks Consensus Estimate of $2.71. Earnings rose 10.2% from the year-ago period.Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported second-quarter earnings of $1.93 per share, down 5.9% year over year.Sales of this drug and medical devices giant came in at $22.45 billion, which beat the Zacks Consensus Estimate of $22.38 billion. Sales rose 4.3% from the year-ago quarter, reflecting an operational increase of 6.6% and a negative currency impact of 2.3%. |
No 3 |
... |
|
Q2-2024 |
|
| |
|
|
|
Johnson & Johnson tops quarterly profit estimates as medical device sales jump.Johnson & Johnson reported first-quarter adjusted earnings that topped expectations as sales in its medical devices business surged. Here’s what J&J reported for the first quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Earnings per share: $2.71 adjusted vs. $2.64 expected Revenue: $21.38 billion vs. $21.4 billion expected |
No 2 |
$2.71 |
|
Q1-2024 |
|
| |
|
|
|
Johnson & Johnson narrowly tops quarterly estimates as pharmaceutical, medtech sales jump. Here’s what J&J reported for the fourth quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $2.29 adjusted vs. $2.28 expected Revenue: $21.40 billion vs. $21.01 billion expected. Johnson & Johnson reported fourth-quarter earnings and revenue that narrowly edged out Wall Street’s expectations. |
No 1 |
$2.29 |
|
Q4-2023 |
|
| |
|
|
|
|
Johnson & Johnson beats on earnings and hikes outlook as medtech, pharmaceutical sales surge.Johnson & Johnson topped quarterly earnings and revenue estimates.Here’s what J&J reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG, formerly known as Refinitiv: Earnings per share: $2.66 adjusted vs. $2.52 expected Revenue: $21.35 billion vs. $21.04 billion expected |
No 4 |
$2.66 |
|
Q3-2023 |
|
| |
|
|
|
Johnson & Johnson beats on earnings, hikes full-year guidance as medtech sales surge. Johnson & Johnson on Thursday reported second-quarter revenue and adjusted earnings that topped Wall Street’s expectations due to strong sales growth from the company’s medtech business. Here’s how J&J results compared with Wall Street expectations, based on a survey of analysts by Refinitiv: Earnings per share: $2.80 adjusted, vs. $2.62 expected Revenue: $25.53 billion, vs. $24.63 billion expected |
No 3 |
$1.19 |
|
Q2-2023 |
|
| |
|
|
|
Johnson & Johnson shares fall after company beats on earnings and revenue, but lowers pharmaceutical sales guidance. The consumer staples giant reported a net loss of $68 million, or 3 cents per share, due to one-time charges related to talc liabilities and the upcoming spinoff of its consumer health business.Here’s how J&J results compared with Wall Street expectations, based on a survey of analysts by Refinitiv: Earnings per share: $2.68 adjusted, vs. $2.50 expected Revenue: $24.75 billion, vs. $23.67 billion expected. Johnson & Johnson reported adjusted earnings and revenue that beat expectations, and raised its full-year guidance, citing strength in units including pharmaceuticals. |
No 2 |
$2.68 |
|
Q1-2023 |
|
| |
|
|
|
J&J Earnings Forecast Beats Street Citing Second-Half Surge. For the quarter, net earnings were $4.1 billion, and diluted earnings per share was $1.70 versus diluted earnings per share of $1.22 a year ago. The company forecast 2023 adjusted earnings of $10.45 to $10.65 a share in a statement , above analysts' average estimate of $10.35 a share. Johnson & Johnson Reports Earnings Results for the Full Year Ended January 01, 2023. Johnson & Johnson reported earnings results for the full year ended January 01, 2023. For the full year, the company reported sales was USD 94,943 million compared to USD 93,775 million a year ago. Net income was USD 17,941 million compared to USD 20,878 million a year ago. Diluted earnings per share from continuing operations was USD 6.73 compared to USD 7.81 a year ago. |
No 1 |
... |
|
Q4-2022 |
|
| |
|
|
|
|
J&J (JNJ) Beats on Q3 Earnings, Cuts 2022 Sales View on Fx Woes.Johnson & Johnson’s JNJ third-quarter 2022 earnings came in at $2.55 per share, which beat the Zacks Consensus Estimate of $2.49. Earnings declined 1.9% from the year-ago period. Earnings slightly missed our estimates of $2.57 per share. Adjusted earnings exclude intangible amortization and some other special items. Including these items, J&J reported third-quarter earnings of $1.68 per share, up 22.6% from the year-ago quarter.Sales of this drug and consumer products giant came in at $23.79 billion, which marginally beat the Zacks Consensus Estimate of $23.28 billion as well as our estimates of $23.64 billion. Sales rose 1.9% from the year-ago quarter, reflecting an operational increase of 8.1% and a negative currency impact of 6.2%. |
No 4 |
... |
|
Q3-2022 |
|
| |
|
|
|
In July 19, 2022, Johnson & Johnson (JNJ) reported strong Q2 2022 earnings, beating expectations with $23.7 billion in sales and $2.77 adjusted EPS, driven by growth in Pharma (Darzalex, Stelara) and Consumer Health (Neutrogena, Imodium) segments, despite currency headwinds impacting overall results. Yahoo Finance covered these results, noting the strong operational performance despite a strengthening dollar affecting reported figures. Total Sales: $23.7 billion (vs. expectations of $22.8 billion). Adjusted Earnings Per Share (EPS): $2.77. |
No 3 |
... |
|
Q2-2022 |
|
| |
|
|
|
J&J lowers 2022 revenue and earnings expectations, stops giving Covid vaccine sales guidance. J&J reported first-quarter sales of $23.4 billion, slightly missing Wall Street expectations but growing 5% over the same quarter last year. The company posted earnings of $2.67 cents per share, beating expectations and increasing 3.1% over the same period of 2021. J&J reported net income of $5.15 billion, a nearly 17% decrease over the first quarter of 2021. Here’s how J&J performed compared with what Wall Street expected, based on analysts’ average estimates compiled by Refinitiv: Adjusted EPS: $2.67 per share, vs. $2.58 expected Revenue: $23.4 billion, vs. $23.6 billion expected |
No 2 |
$2.67 |
|
Q1-2022 |
|
| |
|
|
|
J&J expects more than $3 billion in Covid vaccine sales this year in mixed quarterly report.Johnson & Johnson on Tuesday projected that its Covid vaccine would generate $3 billion to $3.5 billion in sales in 2022, after posting a mixed fourth-quarter report that slightly beat on earnings estimates but missed on revenue. Here’s how J&J performed compared with what Wall Street expected, based on analysts’ average estimates compiled by Refinitiv: Adjusted EPS: $2.13, vs. $2.12 expected. Revenue: $24.8 billion, vs. $25.29 billion expected |
No 1 |
... |
|
Q4-2021 |
|
| |
|
|
|
|
Johnson & Johnson (JNJ) reported its Q3 2021 earnings on October 19, 2021, showing solid performance across its Pharmaceuticals, Medical Devices, and Consumer Health segments, with robust growth particularly in Pharma, as noted by CEO Alex Gorsky. Yahoo Finance provides historical financials for JNJ, including breakdowns for 2021, allowing users to see specific revenue, costs, and earnings figures for that period, though you'd navigate to the "Financials" or "Earnings Calendar" section for details. Reported For: Third Quarter (Q3) of 2021. Highlights: Strong Pharmaceuticals performance, Medical Device recovery, and growth in Consumer Health. |
No 4 |
... |
|
Q3-2021 |
|
| |
|
|
|
Johnson & Johnson expects $2.5 billion in global sales from Covid vaccine this year. Johnson & Johnson said Wednesday it expects to sell $2.5 billion of its Covid-19 vaccine this year, even as concerns mount over the shot’s effectiveness against the delta variant.In releasing its second-quarter financial results, the company also reported earnings and revenue that beat Wall Street’s expectations. Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: Adjusted EPS: $2.48 per share vs $2.27 expected. Revenue: $23.31 billion vs $22.21 billion expected. |
No 3 |
$2.48 |
|
Q2-2021 |
|
| |
|
|
|
Johnson & Johnson reports $100 million in quarterly sales from Covid vaccine. J&J said its pharmaceutical business, which developed the single-shot Covid-19 vaccine, generated $12.19 billion in revenue, a 9.6% year-over-year increase. Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: Adjusted EPS: $2.59 per share vs $2.34 expected. Revenue: $22.32 billion vs $21.98 billion expected. |
No 2 |
$2.59 |
|
Q1-2021 |
|
| |
|
|
|
J&J beats fourth-quarter earnings expectations, will release Covid vaccine data ‘soon’.The drug and and consumer products company reported adjusted earnings of $1.86 per share, higher than the $1.82 expected in a survey of analysts by Refinitiv. Here’s how J&J did compared with what Wall Street expected, according to average estimates compiled by Refinitiv: Adjusted EPS: $1.86 per share versus $1.82 expected. Revenue: $22.48 billion versus $21.67 billion expected. |
No 1 |
$1.86 |
|
Q4-2020 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
| DAILY CHART |
|
|
|
| |
|
|
|
|
|
| WEEKLY CHART |
|
|
|
| |
|
|
|
|
|
| MONTHLY CHART |
|
|
|
| |
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
| DATA INFORMATION |
Johnson and Johnson (JNJ) |
| SOURCE |
Data derived from multiple sources or calculated by Yahoo! Finance |
| WEB |
www.tradingview.com / www.yahoo.com |
| FREQUENCY |
Daily |
| AVAILABILITY |
Daily |
| COVERAGE |
Chart Explained |
| REVISIONS |
No |
| IMPORTANCE |
N/A |
|
| |
|
|
|
|
|
| |
|
|
|
|
|
